Clinical Trial Update: A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of oral rucaparib in patients with BRCA-mutant ovarian cancer and to a lesser extent solid tumors; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Solid Tumor with Evidence of Germline or Somatic Brca

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: pharmaand GmbH | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-12-08